ClinicalTrials.gg

Program

ABP-745

A development code. Also written as “ABP-745 Dose A”, “ABP-745 Dose B” and “ABP-745 Dose C”.

Its studies are mostly in Gout · Atherosclerosis, led by Atom Therapeutics.

Furthest: phase 2, since Aug 13, 20253 company-led studies, 1 open or runningNext primary completion: Jan 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Atom Therapeutics31 open or runningphase 2since Aug 13, 2025Jan 29, 2024Jan 2028phase 2 · NCT07303777

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 29, 2024First study: phase 1 study in GoutFirst studyNCT06258213 · 90 enrolled · United States
  2. Aug 13, 2025Phase 2 study in GoutNCT07145229 · 479 enrolled · United States, Australia, China
  3. Dec 23, 2025Phase 2 study in Atherosclerosis Cardiovascular DiseaseNCT07303777 · 200 planned · United States, Australia, China

Ahead

  1. Jan 2028Primary completion: phase 2 study in Atherosclerosis Cardiovascular DiseaseNCT07303777

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07303777Atherosclerosis Cardiovascular Disease · United States, Australia, China2RecruitingJan 2028200
NCT07145229Gout · United States, Australia, China2CompletedJul 14, 2026479
NCT06258213Gout · United States1CompletedJul 29, 202490

How it is read

Names in the registry

  • “ABP-745 Dose A”, 2 entries
  • “ABP-745 Dose B”, 2 entries
  • “ABP-745 Dose C”, 1 entry
  • “ABP-745”, 1 entry

Codes read as this program: ABP745.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.